Aerie confirms Rhopressa’s mechanism of action in open-angle glaucoma, ocular hypertension

Aerie Pharmaceuticals confirmed the effect of Rhopressa on trabecular meshwork outflow in patients with open-angle glaucoma or ocular hypertension, according to the topline results of a double-masked, randomized, placebo-controlled study designed to evaluate the eye drop’s mechanism of action.

The study enrolled patients diagnosed with open-angle glaucoma or ocular hypertension in both eyes who had unmedicated baseline IOP between 20 mm Hg and 30 mm Hg. The study evaluated the effect of Rhopressa (netarsudil ophthalmic solution 0.02%) on aqueous humor dynamics, according to a company press release.

Rhopressa resulted in a statistically significant increase in trabecular outflow facility of approximately 35% over baseline, according to the release. This was consistent with published results of a study in healthy volunteers in which the drop was found to cause a statistically significant effect on trabecular outflow facility.

A complete study analysis will be presented at a future scientific congress.